Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for Secondary Prevention of Cancer-Related VTE
NCT03080883Phase 3Completed
- Sponsor
- Academic and Community Cancer Research United
- Start
- Jul 2017
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apixaban in venous thromboembolism (VTE), sponsored by Academic and Community Cancer Research United. Started Jul 2017; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03080883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03080883.